<DOC>
	<DOC>NCT00512187</DOC>
	<brief_summary>The study hypothesis is to investigate whether a moderate weight loss (i.e. a weight reduction of at least 5%) could improve the response rate to a suboptimal dose of cyclosporine in patients with severe psoriasis.</brief_summary>
	<brief_title>Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>18 years of age,active but clinically stable plaque psoriasis involving at least 10 percent of the body surface area and a psoriasis area and severity index (PASI) score ≥10 and a body mass index ≥30. Other type of psoriasis (guttate, erythrodermic and pustular psoriasis) Uncontrolled hypertension Severe congestive heart failure Renal and liver impairment Active or chronic infections, including HIV, HBV and HCV infections, latent tuberculosis Previous or active malignancies Pregnancy and lactations Previous treatment with cyclosporine Phototherapy or any systemic or topical therapy for psoriasis within the previous 4 weeks before enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>